Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-30

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies.

Specifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated.

Finally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Relapse Presence in Multiple Sclerosis

NCT05218317

Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis Relapse

COMPLETED

Relıabılıty and valıdıty of the Two-minute Test wıth Multiple Sclerosis

NCT06849960

Multiple Sclerosis

ENROLLING_BY_INVITATION

Measuring Active Microglia in Progressive Multiple Sclerosis

NCT02207075

Secondary Progressive Multiple Sclerosis

COMPLETED

An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period

NCT01112657

Multiple Sclerosis

COMPLETED

Study of myMS in Participants With a Diagnosis of Multiple Sclerosis

NCT03111394

Multiple Sclerosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, MS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

People with MS

30 People with MS

No interventions assigned to this group

Health Control

30 Health Control

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older diagnosed with MS or CIS according to the 2017 McDonald criteria.
* No diagnosis of any autoimmune disease or malignancy.
* No new diagnosis of autoimmune disease or malignancy during the 1-year follow-up period.
* No use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.
* No vaccination within one month prior to blood sampling.
* Not in the menstrual cycle at the time of blood sampling.

Exclusion Criteria

* Age below 18 years.
* Presence of a previous or newly diagnosed autoimmune disease or malignancy at the time of blood sampling.
* Use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.
* Vaccination within one month prior to blood sampling
* Being in the menstrual cycle at the time of blood sampling
* Patients without a definitive MS diagnosis according to the 2017 McDonald criteria will not be included in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes